封面
市場調查報告書
商品編碼
1413660

陰道炎治療藥物市場:按藥物類型、給藥方式、給藥途徑和配銷通路- 全球預測,2024-2030 年

Vaginitis Therapeutics Market by Drug Type (Anti-bacterial, Anti-fungal, Hormone), Offering (Over-The-Counter (OTC), Prescription), Route of Administration, Distribution Channel - Global Forecast 2024-2030

出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2個工作天內

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計2023年陰道炎治療藥物市場規模為26億美元,預計2024年將達27.6億美元,2030年將達46.8億美元,複合年成長率為8.75%。

陰道炎治療的全球市場

主要市場統計
基準年[2023] 26億美元
預測年份 [2024] 27.6億美元
預測年份 [2030] 46.8億美元
複合年成長率(%) 8.75%
陰道炎治療藥物市場-IMG1

FPNV定位矩陣

FPNV定位矩陣對於評估陰道炎治療市場至關重要。我們檢視與業務策略和產品滿意度相關的關鍵指標,以對供應商進行全面評估。這種深入的分析使用戶能夠根據自己的要求做出資訊的決策。根據評估,供應商被分為四個成功程度不同的像限:前沿(F)、探路者(P)、利基(N)和重要(V)。

市場佔有率分析

市場佔有率分析是一種綜合工具,可以對陰道炎治療藥物市場供應商的現狀進行深入而深入的研究。全面比較和分析供應商在整體收益、基本客群和其他關鍵指標方面的貢獻,以便更好地了解公司的績效及其在爭奪市場佔有率時面臨的挑戰。此外,該分析還提供了對該行業競爭特徵的寶貴考察,包括在研究基準年觀察到的累積、分散主導地位和合併特徵等因素。這種詳細程度的提高使供應商能夠做出更資訊的決策並制定有效的策略,從而在市場上獲得競爭優勢。

該報告對以下幾個方面提供了寶貴的見解:

1-市場滲透率:提供有關主要企業所服務的市場的全面資訊。

2-市場開拓:我們深入研究利潤豐厚的新興市場,並分析它們在成熟細分市場中的滲透率。

3- 市場多元化:提供有關新產品發布、開拓地區、最新發展和投資的詳細資訊。

4-競爭力評估與資訊:對主要企業的市場佔有率、策略、產品、認證、監管狀況、專利狀況、製造能力等進行全面評估。

5- 產品開發與創新:提供對未來技術、研發活動和突破性產品開發的見解。

本報告解決了以下關鍵問題:

1-陰道炎治療藥物市場的市場規模和預測是多少?

2-在陰道炎治療藥物市場預測期內需要考慮投資的產品、細分市場、應用和領域有哪些?

3-陰道炎治療藥物市場的技術趨勢和法律規範是什麼?

4-陰道炎治療藥物市場主要供應商的市場佔有率是多少?

5-進入陰道炎治療藥物市場的合適型態和策略手段是什麼?

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 由於感染疾病導致陰道炎的盛行率增加
      • 人們越來越意識到性健康如何影響女性
      • 人們越來越偏好微創醫療程序和先進的陰道產品
    • 抑制因素
      • 治療陰道炎費用昂貴
    • 機會
      • 陰道感染疾病診斷和治療的技術進步
      • 對用於治療陰道炎的凝膠和乳膏等標靶給藥系統的需求
    • 任務
      • 與使用陰道炎藥物相關的副作用
  • 市場區隔分析
  • 市場趨勢分析
  • 高通膨的累積效應
  • 波特五力分析
  • 價值鍊和關鍵路徑分析
  • 法律規範

第 6 章:按藥物類型分類的陰道炎治療藥物市場

  • 抗菌的
  • 抗真菌劑
  • 荷爾蒙

第7章陰道炎治療藥物市場:透過提供

  • 店面銷售(OTC)
  • 處方箋

第8章陰道炎治療藥物市場:給藥給藥途徑

  • 口服
  • 局部的

第9章陰道炎治療藥物市場:依配銷通路

  • 醫院
  • 藥局
    • 離線
    • 線上的

第10章 北美及南美陰道炎治療藥物市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章亞太陰道炎治療藥物市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章 歐洲、中東和非洲陰道炎治療藥物市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭形勢

  • FPNV定位矩陣
  • 市場佔有率分析:主要企業
  • 主要企業競爭情境分析

第14章競爭產品組合

  • 主要公司簡介
    • AbbVie Inc.
    • Bausch Health Companies Inc.
    • Bayer AG
    • Cipla Ltd.
    • Dare Bioscience, Inc.
    • Dr Reddy's Laboratories Ltd
    • Eli Lilly and Company
    • Enzo Biochem Inc.
    • Janssen Pharmaceuticals Inc.
    • Lumavita AG
    • Lupin Pharmaceuticals Inc.
    • Merck & Co., Inc.
    • Mission Pharmacal Company
    • Mylan NV
    • Novartis AG
    • Novo Nordisk A/S
    • Perrigo Company plc
    • Pfizer Inc.
    • PhagoMed Biopharma GmbH
    • Sanofi SA
    • Starpharma Holdings Limited
    • Sun Pharmaceutical Industries Limited
    • TenNor Therapeutics Ltd
    • Teva Pharmaceutical Industries Ltd.
    • Tolmar Pharmaceuticals, Inc.
  • 主要產品系列

第15章附錄

  • 討論指南
  • 關於許可證和定價
Product Code: MRR-8E22B61932E8

[196 Pages Report] The Vaginitis Therapeutics Market size was estimated at USD 2.60 billion in 2023 and expected to reach USD 2.76 billion in 2024, at a CAGR 8.75% to reach USD 4.68 billion by 2030.

Global Vaginitis Therapeutics Market

KEY MARKET STATISTICS
Base Year [2023] USD 2.60 billion
Estimated Year [2024] USD 2.76 billion
Forecast Year [2030] USD 4.68 billion
CAGR (%) 8.75%
Vaginitis Therapeutics Market - IMG1

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Vaginitis Therapeutics Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Vaginitis Therapeutics Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Vaginitis Therapeutics Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Bausch Health Companies Inc., Bayer AG, Cipla Ltd., Dare Bioscience, Inc., Dr Reddy's Laboratories Ltd, Eli Lilly and Company, Enzo Biochem Inc., Janssen Pharmaceuticals Inc., Lumavita AG, Lupin Pharmaceuticals Inc., Merck & Co., Inc., Mission Pharmacal Company, Mylan NV, Novartis AG, Novo Nordisk A/S, Perrigo Company plc, Pfizer Inc., PhagoMed Biopharma GmbH, Sanofi S.A., Starpharma Holdings Limited, Sun Pharmaceutical Industries Limited, TenNor Therapeutics Ltd, Teva Pharmaceutical Industries Ltd., and Tolmar Pharmaceuticals, Inc..

Market Segmentation & Coverage

This research report categorizes the Vaginitis Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Drug Type
    • Anti-bacterial
    • Anti-fungal
    • Hormone
  • Offering
    • Over-The-Counter (OTC)
    • Prescription
  • Route of Administration
    • Oral
    • Topical
  • Distribution Channel
    • Hospital
    • Pharmacies
      • Offline
      • Online
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Vaginitis Therapeutics Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Vaginitis Therapeutics Market?

3. What are the technology trends and regulatory frameworks in the Vaginitis Therapeutics Market?

4. What is the market share of the leading vendors in the Vaginitis Therapeutics Market?

5. Which modes and strategic moves are suitable for entering the Vaginitis Therapeutics Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Vaginitis Therapeutics Market, by Region

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of vaginitis caused by infections
      • 5.1.1.2. Increasing awareness about the impacts of sexual health on women
      • 5.1.1.3. Growing preference for minimally invasive medical procedures and advanced vaginal products
    • 5.1.2. Restraints
      • 5.1.2.1. High cost associated with the treatment of vaginitis
    • 5.1.3. Opportunities
      • 5.1.3.1. Technological advancement in diagnostics and therapeutics for treating vaginal infections
      • 5.1.3.2. Demand for targeted delivery systems such as gels and creams for treating vaginitis
    • 5.1.4. Challenges
      • 5.1.4.1. Side effects associated with the use of vaginitis medications
  • 5.2. Market Segmentation Analysis
  • 5.3. Market Trend Analysis
  • 5.4. Cumulative Impact of High Inflation
  • 5.5. Porter's Five Forces Analysis
    • 5.5.1. Threat of New Entrants
    • 5.5.2. Threat of Substitutes
    • 5.5.3. Bargaining Power of Customers
    • 5.5.4. Bargaining Power of Suppliers
    • 5.5.5. Industry Rivalry
  • 5.6. Value Chain & Critical Path Analysis
  • 5.7. Regulatory Framework

6. Vaginitis Therapeutics Market, by Drug Type

  • 6.1. Introduction
  • 6.2. Anti-bacterial
  • 6.3. Anti-fungal
  • 6.4. Hormone

7. Vaginitis Therapeutics Market, by Offering

  • 7.1. Introduction
  • 7.2. Over-The-Counter (OTC)
  • 7.3. Prescription

8. Vaginitis Therapeutics Market, by Route of Administration

  • 8.1. Introduction
  • 8.2. Oral
  • 8.3. Topical

9. Vaginitis Therapeutics Market, by Distribution Channel

  • 9.1. Introduction
  • 9.2. Hospital
  • 9.3. Pharmacies
    • 9.4.1. Offline
    • 9.4.2. Online

10. Americas Vaginitis Therapeutics Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Vaginitis Therapeutics Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Vaginitis Therapeutics Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. FPNV Positioning Matrix
  • 13.2. Market Share Analysis, By Key Player
  • 13.3. Competitive Scenario Analysis, By Key Player

14. Competitive Portfolio

  • 14.1. Key Company Profiles
    • 14.1.1. AbbVie Inc.
    • 14.1.2. Bausch Health Companies Inc.
    • 14.1.3. Bayer AG
    • 14.1.4. Cipla Ltd.
    • 14.1.5. Dare Bioscience, Inc.
    • 14.1.6. Dr Reddy's Laboratories Ltd
    • 14.1.7. Eli Lilly and Company
    • 14.1.8. Enzo Biochem Inc.
    • 14.1.9. Janssen Pharmaceuticals Inc.
    • 14.1.10. Lumavita AG
    • 14.1.11. Lupin Pharmaceuticals Inc.
    • 14.1.12. Merck & Co., Inc.
    • 14.1.13. Mission Pharmacal Company
    • 14.1.14. Mylan NV
    • 14.1.15. Novartis AG
    • 14.1.16. Novo Nordisk A/S
    • 14.1.17. Perrigo Company plc
    • 14.1.18. Pfizer Inc.
    • 14.1.19. PhagoMed Biopharma GmbH
    • 14.1.20. Sanofi S.A.
    • 14.1.21. Starpharma Holdings Limited
    • 14.1.22. Sun Pharmaceutical Industries Limited
    • 14.1.23. TenNor Therapeutics Ltd
    • 14.1.24. Teva Pharmaceutical Industries Ltd.
    • 14.1.25. Tolmar Pharmaceuticals, Inc.
  • 14.2. Key Product Portfolio

15. Appendix

  • 15.1. Discussion Guide
  • 15.2. License & Pricing

LIST OF FIGURES

  • FIGURE 1. VAGINITIS THERAPEUTICS MARKET RESEARCH PROCESS
  • FIGURE 2. VAGINITIS THERAPEUTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. VAGINITIS THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. VAGINITIS THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. VAGINITIS THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. VAGINITIS THERAPEUTICS MARKET DYNAMICS
  • FIGURE 7. VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
  • FIGURE 8. VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2023 VS 2030 (%)
  • FIGURE 10. VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 12. VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 14. VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. AMERICAS VAGINITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 16. AMERICAS VAGINITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. UNITED STATES VAGINITIS THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 18. UNITED STATES VAGINITIS THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. ASIA-PACIFIC VAGINITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. ASIA-PACIFIC VAGINITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 23. VAGINITIS THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023
  • FIGURE 24. VAGINITIS THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023

LIST OF TABLES

  • TABLE 1. VAGINITIS THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. VAGINITIS THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 6. VAGINITIS THERAPEUTICS MARKET SIZE, BY ANTI-BACTERIAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. VAGINITIS THERAPEUTICS MARKET SIZE, BY ANTI-FUNGAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 8. VAGINITIS THERAPEUTICS MARKET SIZE, BY HORMONE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 10. VAGINITIS THERAPEUTICS MARKET SIZE, BY OVER-THE-COUNTER (OTC), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. VAGINITIS THERAPEUTICS MARKET SIZE, BY PRESCRIPTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 13. VAGINITIS THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. VAGINITIS THERAPEUTICS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 16. VAGINITIS THERAPEUTICS MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 19. VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFLINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. VAGINITIS THERAPEUTICS MARKET SIZE, BY ONLINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS VAGINITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 35. BRAZIL VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 36. BRAZIL VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 37. CANADA VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. CANADA VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 39. CANADA VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 40. CANADA VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 41. CANADA VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 42. MEXICO VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. MEXICO VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 44. MEXICO VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 45. MEXICO VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 46. MEXICO VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. UNITED STATES VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 49. UNITED STATES VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 50. UNITED STATES VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 51. UNITED STATES VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 52. UNITED STATES VAGINITIS THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 53. ASIA-PACIFIC VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. ASIA-PACIFIC VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 55. ASIA-PACIFIC VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 56. ASIA-PACIFIC VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 57. ASIA-PACIFIC VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 58. ASIA-PACIFIC VAGINITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 59. AUSTRALIA VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. AUSTRALIA VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 61. AUSTRALIA VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 62. AUSTRALIA VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 63. AUSTRALIA VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 64. CHINA VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. CHINA VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 66. CHINA VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 67. CHINA VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 68. CHINA VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 69. INDIA VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. INDIA VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 71. INDIA VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 72. INDIA VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 73. INDIA VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 74. INDONESIA VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. INDONESIA VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 76. INDONESIA VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 77. INDONESIA VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 78. INDONESIA VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 79. JAPAN VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. JAPAN VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 81. JAPAN VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 82. JAPAN VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 83. JAPAN VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 84. MALAYSIA VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. MALAYSIA VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 86. MALAYSIA VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 87. MALAYSIA VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 88. MALAYSIA VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 89. PHILIPPINES VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. PHILIPPINES VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 91. PHILIPPINES VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 92. PHILIPPINES VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 93. PHILIPPINES VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 94. SINGAPORE VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. SINGAPORE VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 96. SINGAPORE VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 97. SINGAPORE VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 98. SINGAPORE VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 99. SOUTH KOREA VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. SOUTH KOREA VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 101. SOUTH KOREA VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 102. SOUTH KOREA VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 103. SOUTH KOREA VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 104. TAIWAN VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. TAIWAN VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 106. TAIWAN VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 107. TAIWAN VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 108. TAIWAN VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 109. THAILAND VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. THAILAND VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 111. THAILAND VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 112. THAILAND VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 113. THAILAND VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 114. VIETNAM VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. VIETNAM VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 116. VIETNAM VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 117. VIETNAM VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 118. VIETNAM VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 119. EUROPE, MIDDLE EAST & AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. EUROPE, MIDDLE EAST & AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 121. EUROPE, MIDDLE EAST & AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 122. EUROPE, MIDDLE EAST & AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 123. EUROPE, MIDDLE EAST & AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 124. EUROPE, MIDDLE EAST & AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 125. DENMARK VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. DENMARK VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 127. DENMARK VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 128. DENMARK VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 129. DENMARK VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 130. EGYPT VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. EGYPT VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 132. EGYPT VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 133. EGYPT VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 134. EGYPT VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 135. FINLAND VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. FINLAND VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 137. FINLAND VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 138. FINLAND VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 139. FINLAND VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 140. FRANCE VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. FRANCE VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 142. FRANCE VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 143. FRANCE VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 144. FRANCE VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 145. GERMANY VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. GERMANY VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 147. GERMANY VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 148. GERMANY VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 149. GERMANY VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 150. ISRAEL VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 151. ISRAEL VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 152. ISRAEL VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 153. ISRAEL VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 154. ISRAEL VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 155. ITALY VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 156. ITALY VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 157. ITALY VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 158. ITALY VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 159. ITALY VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 160. NETHERLANDS VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 161. NETHERLANDS VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 162. NETHERLANDS VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 163. NETHERLANDS VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 164. NETHERLANDS VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 165. NIGERIA VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 166. NIGERIA VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 167. NIGERIA VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 168. NIGERIA VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 169. NIGERIA VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 170. NORWAY VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 171. NORWAY VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 172. NORWAY VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 173. NORWAY VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 174. NORWAY VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 175. POLAND VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 176. POLAND VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 177. POLAND VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 178. POLAND VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 179. POLAND VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 180. QATAR VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 181. QATAR VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 182. QATAR VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 183. QATAR VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 184. QATAR VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 185. RUSSIA VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 186. RUSSIA VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 187. RUSSIA VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 188. RUSSIA VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 189. RUSSIA VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 190. SAUDI ARABIA VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 191. SAUDI ARABIA VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 192. SAUDI ARABIA VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 193. SAUDI ARABIA VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 194. SAUDI ARABIA VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 195. SOUTH AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 196. SOUTH AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 197. SOUTH AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 198. SOUTH AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 199. SOUTH AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 200. SPAIN VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 201. SPAIN VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 202. SPAIN VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 203. SPAIN VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 204. SPAIN VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 205. SWEDEN VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 206. SWEDEN VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 207. SWEDEN VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 208. SWEDEN VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 209. SWEDEN VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 210. SWITZERLAND VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 211. SWITZERLAND VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 212. SWITZERLAND VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 213. SWITZERLAND VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 214. SWITZERLAND VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 215. TURKEY VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 216. TURKEY VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 217. TURKEY VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 218. TURKEY VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 219. TURKEY VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 220. UNITED ARAB EMIRATES VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 221. UNITED ARAB EMIRATES VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 222. UNITED ARAB EMIRATES VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 223. UNITED ARAB EMIRATES VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 224. UNITED ARAB EMIRATES VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 225. UNITED KINGDOM VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 226. UNITED KINGDOM VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 227. UNITED KINGDOM VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 228. UNITED KINGDOM VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 229. UNITED KINGDOM VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 230. VAGINITIS THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023
  • TABLE 231. VAGINITIS THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 232. VAGINITIS THERAPEUTICS MARKET LICENSE & PRICING